by EpicentRx | May 8, 2024 | Blog
The Phase 2b clinical trial with RRx-001 (nibrozetone) against chemotherapy and radiation-induced severe oral mucositis (SOM), called KEVLARx, takes its name, obviously, from the bulletproof polymer called Kevlar® that was invented at DuPont™. The hope is that the...
by EpicentRx | May 7, 2024 | Blog
How do you spell mouth? As above, right? Yes, unless you develop severe oral mucositis (SOM) from the treatment of head and neck cancer in which case that spelling – and pronunciation – definitively changes to “m-o-w-t-h”. The o-w is for OW!!!!! As in OW,...
by EpicentRx | May 6, 2024 | Blog
The KEVLARx Bullet Train has finally left the station. Tickets please. Final destination: head-and-neck cancer with stops at several top-notch clinical trial sites and institutions along the way. These sites are the following, with more coming soon: The Ohio State...
by EpicentRx | May 6, 2024 | Blog
“Distaff? What about datstaff?” Distaff Definition (noun): a stick around which wool is wound for spinning. Definition (adjective): of or concerning women. Pronunciation: dist-aaf Example sentences: “Distaff is an old word that appears in...
by EpicentRx | May 3, 2024 | Blog
All aboard the KEVLARx bullet train! Destination: head and neck cancer (HNC) without a stop, hopefully, at severe oral mucositis. En route over the following week, as a quick, handy reference, watch for a series of “bullet blogs” with fast facts on RRx-001...
